Cellular reprogramming for the scalable production of human cells

Developing a new generation of consistent and scalable human cell models

Date & Time

July 28, 2020 | 9 am PDT (6pm CEST)

Webinar Description

Advances in cellular reprogramming have opened new doors for studying human cells in health and disease, drug discovery, and the development of cell therapies. Widespread use of human-induced pluripotent stem cell (hiPSC)-derived mature cell types, however, is restricted by complex differentiation protocols and inefficient reprogramming methods.

Bit Bio is developing a platform capable of producing consistent and functional batches every human cell type, with the help of Twist genes.

In this webinar you will:
  • Review fundamental concepts of cellular reprogramming.
  • Hear how Bit Bio’s novel gene engineering approach, opti-ox™, enables precisely controlled expression of transcription factors, and as a result, deterministic induction of a new cell identity.
  • See how Twist’s Clonal Genes and custom vector onboarding have allowed Bit Bio to streamline their molecular cloning of transcription factors required for cellular reprogramming.
  • Explore examples of different validated cell models that have been developed using this approach.
Webinar Registration

Speaker

Dr. Michael D'Angelo
Senior Scientist | Bit Bio

About the speaker:
Michael is a molecular biologist and genome engineer. He leads the Bit Bio team conducting technology development and gene editing projects, which are at the core of all Bit Bio’s cellular reprogramming activities.

About the company:
Bit Bio is an award-winning human synthetic biology enterprise. Bit Bio's mission is to code cells to advance the wellbeing of humanity. To do so, they apply the principles of computation to biology. Bit Bio’s current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies.
©2020. All Rights Reserved Twist Bioscience Inc.